Stamatiou Rodopi, Kararigas Georgios
Department of Physiology, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
School of Biology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Am Heart J Plus. 2024 Jul 3;44:100420. doi: 10.1016/j.ahjo.2024.100420. eCollection 2024 Aug.
Transgender persons face increased risk in developing cardiovascular diseases due to administration of hormonal therapy used for gender expression, or due to the presence of other risk factors, such as minority stress and difficulty to have full access to health care. Even though the need for gender diversity in research has been identified, the number of clinical trials including transgender persons remains low. The aim of this study was to highlight gaps in inclusion of transgender individuals in cardiovascular clinical research.
A search in the pubmed.com database, as well as in the clinicaltrials.gov repository, was performed with search terms regarding transgender persons and cardiovascular diseases.
The inclusion of transgender persons in cardiovascular clinical trials was evaluated.
This study revealed that there is only a small number of cardiovascular clinical trials including or studying transgender persons. This finding demonstrates the overall lack of clinical trials regarding cardiovascular health in transgender individuals and is indicative of their under-representation in clinical research.
由于用于性别表达的激素疗法,或由于其他风险因素的存在,如少数群体压力和难以充分获得医疗保健,跨性别者患心血管疾病的风险增加。尽管已经认识到研究中性别多样性的必要性,但纳入跨性别者的临床试验数量仍然很少。本研究的目的是突出跨性别个体在心血管临床研究纳入方面的差距。
在pubmed.com数据库以及clinicaltrials.gov库中,使用关于跨性别者和心血管疾病的搜索词进行了搜索。
评估跨性别者在心血管临床试验中的纳入情况。
本研究表明,仅有少数心血管临床试验纳入或研究跨性别者。这一发现表明,总体上缺乏关于跨性别个体心血管健康的临床试验,并且表明他们在临床研究中的代表性不足。